Implantable Cardiac Rhythm Management Device Market Report 2025

The implantable cardiac rhythm management device market size has grown steadily in recent years. It will grow from $17.06 billion in 2024 to $17.87 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to the aging population, increasing incidence of cardiac arrhythmias, awareness and education initiatives, healthcare infrastructure development, and rising healthcare expenditure.

The implantable cardiac rhythm management device market size is expected to see strong growth in the next few years. It will grow to $23.27 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to a shift towards leadless devices, remote patient monitoring, a focus on heart failure management, increased adoption in emerging markets, and collaborations for research and development. Major trends in the forecast period include the emergence of bioresorbable technologies, integration of artificial intelligence (AI), advancements in technology, remote monitoring and telemedicine integration, advancements in leadless pacemakers, wireless charging, and power management.

The rising incidence of cardiac disorders is anticipated to significantly enhance the growth of the implantable cardiac rhythm management devices market. Cardiac disorders refer to conditions that impact the heart or blood vessels. Implantable cardiac rhythm management devices are designed to assist patients with heart failure and diminished left ventricular function by improving systolic function through the resynchronization of heart contractions and restoring normal rhythm during life-threatening rapid ventricular arrhythmias. As a result, the growing prevalence of cardiac disorders will drive demand for these devices. For instance, in September 2024, data from the British Heart Foundation, a UK-based cardiovascular research charity, revealed that approximately 7.6 million individuals in the UK are affected by heart and circulatory diseases. This includes about 4 million men and 3.6 million women living with these conditions, which account for roughly 27% of all deaths in the UK, translating to over 170,000 fatalities each year, or about 480 deaths per day - equivalent to one death every three minutes. Therefore, the increasing prevalence of cardiac disorders is a key factor propelling the growth of the implantable cardiac rhythm management devices market.

The growing aging population is anticipated to significantly drive the growth of the implantable cardiac rhythm management devices market in the coming years. An aging population refers to a demographic trend where a significant portion of a country's citizens are becoming older, leading to a higher average age among its residents. Implantable cardiac rhythm management devices are frequently utilized within this demographic to address and manage various heart-related issues. For example, in January 2024, the Population Reference Bureau, a US-based nonprofit organization, projected that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Additionally, this age group's proportion of the total population is expected to increase from 17% to 23% over the same period. Consequently, the expanding aging population is a key factor propelling the growth of the implantable cardiac rhythm management devices market.

Technological advancement stands out as a prominent trend in the implantable cardiac rhythm management devices market, with major companies focusing on developing innovative technologies to maintain their market position. Rhythm Management Group PLLC, a US-based company, introduced RhythmSynergy in April 2022, a technology platform that utilizes machine learning to deliver timely clinical insights for patients monitored remotely with implantable cardiac devices and wearable devices. This platform streamlines the review processes by combining clinical knowledge and machine learning technologies, making it simpler to review, share, and analyze patient data.

Major companies in the implantable cardiac rhythm management devices market prioritize the launch of innovative products such as implantable cardiac defibrillators. In October 2023, MicroPort CRM, a France-based manufacturer, launched the ULYS Implantable Cardioverter Defibrillator (ICDs) and INVICTA defibrillation implantable devices. The ULYS ICD integrates cutting-edge technology with minimal energy consumption, featuring the AutoMRI function and PARAD arrhythmia discrimination algorithm. The INVICTA defibrillation lead consistently senses electrical signals from the right ventricle, providing pacing therapy if the heart rate is too low.

In August 2022, Medtronic, a US-based medical technology company, completed the acquisition of Affera Inc. for an undisclosed amount. This acquisition grants Medtronic access to the Affera Prism-1TM cardiac mapping and navigation platform, compatible with both Medtronic therapeutic catheters and various competing technologies. Affera Inc., a US-based medical technology company, specializes in manufacturing cardiac mapping and navigation systems for treating patients with cardiac arrhythmias.

Major companies operating in the implantable cardiac rhythm management device market include Schiller AG, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Koninklijke Philips N.V., Zoll Medical Corporation, Biotronik Ltd., MicroPort Scientific Corporation, Abiomed Inc, Nihon Kohden Corporation, Japan Lifeline Co. Ltd., Lepu Medical Technology Co. Ltd., LivaNova PLC, Shenzhen Mindray Biomedical Electronics Co. Ltd, Progetti Srl, Edwards Lifesciences Corporation, Cardiac Science Corporation, Bardy Diagnostics Inc., Beijing Demax Medical Technology Co. Ltd, iRhythm Technologies Inc., Impulse Dynamics plc., VytronUS Inc.

North America was the largest region in the implantable cardiac rhythm management device market in 2024. The regions covered in the implantable cardiac rhythm management device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable cardiac rhythm management device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Implantable cardiac rhythm management devices are small battery-operated devices that are surgically inserted inside the body and connected to the heart, playing a crucial role in maintaining and managing heart rhythm.

The primary devices in the category of implantable cardiac rhythm management devices include cardiac resynchronization therapy, defibrillators, and pacemakers. Cardiac resynchronization therapy (CRT) is a specialized treatment designed for severe cardiac rhythm issues. These devices find applications in various conditions such as bradycardia, tachycardia, and others, and are utilized in hospitals, specialty cardiac centers, and other medical settings.

The implantable cardiac rhythm management device market research report is one of a series of new reports that provides implantable cardiac rhythm management device market statistics, including implantable cardiac rhythm management device industry global market size, regional shares, competitors with implantable cardiac rhythm management device market share, detailed implantable cardiac rhythm management device market segments, market trends, and opportunities, and any further data you may need to thrive in the implantable cardiac rhythm management device industry. This implantable cardiac rhythm management device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The implantable cardiac rhythm management devices market consists of sales of the leadless pacemaker, insertable cardiac monitor, cardiac leads, and subcutaneous implantable defibrillator (S-ICD). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.